Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Progyny Yönetim

Yönetim kriter kontrolleri 4/4

Progyny's CEO'su Pete Anevski, Jan2022 tarihinde atandı, in görev süresi 2.75 yıldır. in toplam yıllık tazminatı $ 1.09M olup, şirket hissesi ve opsiyonları dahil olmak üzere 45.7% maaş ve 54.3% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.16% ine doğrudan sahiptir ve bu hisseler $ 2.45M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 7.6 yıldır.

Anahtar bilgiler

Pete Anevski

İcra Kurulu Başkanı

US$1.1m

Toplam tazminat

CEO maaş yüzdesi45.7%
CEO görev süresi2.8yrs
CEO sahipliği0.2%
Yönetim ortalama görev süresi2.8yrs
Yönetim Kurulu ortalama görev süresi7.6yrs

Son yönetim güncellemeleri

Recent updates

Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors

Sep 29
Progyny, Inc.'s (NASDAQ:PGNY) Stock Retreats 28% But Earnings Haven't Escaped The Attention Of Investors

Progyny: Downgrading As Uncertainties Increase

Aug 15

Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing

Aug 11
Progyny, Inc. (NASDAQ:PGNY) Stocks Pounded By 25% But Not Lagging Market On Growth Or Pricing

At US$27.79, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?

Jul 20
At US$27.79, Is Progyny, Inc. (NASDAQ:PGNY) Worth Looking At Closely?

Progyny: Recent Stock Decline Provides Buying Opportunity

Jul 12

Progyny's (NASDAQ:PGNY) Returns Have Hit A Wall

Jun 23
Progyny's (NASDAQ:PGNY) Returns Have Hit A Wall

Progyny: At This Price, Secular Tailwinds Are Too Compelling To Ignore

Jun 10

Progyny: No Change To Long-Term Outlook

Jun 04

Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price

Apr 29
Why We're Not Concerned About Progyny, Inc.'s (NASDAQ:PGNY) Share Price

Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

Apr 03
Is Now An Opportune Moment To Examine Progyny, Inc. (NASDAQ:PGNY)?

Progyny: Long-Term Outlook Remains Positive, Reiterate Buy

Mar 15

Progyny: Long-Term Thesis Still Intact

Mar 09

Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher

Mar 01
Progyny's (NASDAQ:PGNY) Returns On Capital Are Heading Higher

Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable

Jan 07
Progyny, Inc.'s (NASDAQ:PGNY) P/E Still Appears To Be Reasonable

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Dec 11
Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Nov 08
Returns Are Gaining Momentum At Progyny (NASDAQ:PGNY)

Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

Aug 24
Is Progyny, Inc. (NASDAQ:PGNY) Potentially Undervalued?

There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital

Aug 06
There's Been No Shortage Of Growth Recently For Progyny's (NASDAQ:PGNY) Returns On Capital

Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital

May 06
Progyny (NASDAQ:PGNY) Is Looking To Continue Growing Its Returns On Capital

When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?

Jan 25
When Should You Buy Progyny, Inc. (NASDAQ:PGNY)?

Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue

Dec 12
Progyny (NASDAQ:PGNY) Shareholders Will Want The ROCE Trajectory To Continue

Is It Time To Consider Buying Progyny, Inc. (NASDAQ:PGNY)?

Oct 18
Is It Time To Consider Buying Progyny, Inc. (NASDAQ:PGNY)?

CEO Tazminat Analizi

Pete Anevski'un ücretlendirmesi Progyny'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Jun 30 2024n/an/a

US$63m

Mar 31 2024n/an/a

US$61m

Dec 31 2023US$1mUS$500k

US$62m

Sep 30 2023n/an/a

US$52m

Jun 30 2023n/an/a

US$49m

Mar 31 2023n/an/a

US$43m

Dec 31 2022US$69mUS$500k

US$30m

Sep 30 2022n/an/a

US$42m

Jun 30 2022n/an/a

US$46m

Mar 31 2022n/an/a

US$56m

Dec 31 2021US$786kUS$425k

US$66m

Sep 30 2021n/an/a

US$90m

Jun 30 2021n/an/a

US$78m

Mar 31 2021n/an/a

US$58m

Dec 31 2020US$910kUS$425k

US$46m

Sep 30 2020n/an/a

US$3m

Jun 30 2020n/an/a

-US$10m

Mar 31 2020n/an/a

-US$5m

Dec 31 2019US$5mUS$375k

-US$9m

Sep 30 2019n/an/a

-US$6m

Jun 30 2019n/an/a

US$1m

Mar 31 2019n/an/a

-US$4m

Dec 31 2018US$682kUS$325k

-US$6m

Tazminat ve Piyasa: Pete 'nin toplam tazminatı ($USD 1.09M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın altındadır ($USD 5.54M ).

Tazminat ve Kazançlar: Pete 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.


CEO

Pete Anevski (57 yo)

2.8yrs

Görev süresi

US$1,093,512

Tazminat

Mr. Peter Anevski, also known as Pete, has been Chief Executive Officer and Director of Progyny, Inc. since January 2022 and had been its President since June 2019 until December 31, 2021 and was its Chief...


Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
David Schlanger
Executive Chairman7.6yrsUS$513.57k0.055%
$ 806.1k
Peter Anevski
CEO & Director2.8yrsUS$1.09m0.16%
$ 2.4m
Michael Sturmer
President2.8yrsUS$1.49m0.073%
$ 1.1m
Mark Livingston
Chief Financial Officer4.1yrsUS$1.40m0.049%
$ 724.3k
Allison Swartz
Executive VP1.9yrsUS$546.22k0.018%
$ 271.1k
Steven Leist
Chief Technology Officerless than a yearVeri yokVeri yok
James Hart
Vice President of Investor Relationsno dataVeri yokVeri yok
Risa Fisher
Chief Marketing Officerno dataVeri yokVeri yok
Cassandra Pratt
Chief Human Resources Officerno dataVeri yokVeri yok
Julie Stadlbauer
Chief Business Development Officer2.8yrsVeri yokVeri yok
Janet Choi
Member of the Medical Advisory Board & Chief Medical Officer1.5yrsVeri yokVeri yok
Arielle Bogorad
Senior Vice President of Employer Market Strategy2.4yrsVeri yokVeri yok

2.8yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: PGNY 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).


Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
David Schlanger
Executive Chairman7.6yrsUS$513.57k0.055%
$ 806.1k
Peter Anevski
CEO & Director2.8yrsUS$1.09m0.16%
$ 2.4m
Janet Choi
Member of the Medical Advisory Board & Chief Medical Officerno dataVeri yokVeri yok
Norman Payson
Independent Director7.8yrsUS$567.30k0.45%
$ 6.6m
Fred Cohen
Independent Director9.6yrsUS$583.35k0.013%
$ 197.8k
Beth Seidenberg
Lead Independent Director14.4yrsUS$653.39k0.29%
$ 4.2m
Kevin Gordon
Independent Director5yrsUS$518.30k0.0069%
$ 101.1k
Jeffrey Park
Independent Director5yrsUS$606.88k0.013%
$ 197.8k
Alan Copperman
Member of the Medical Advisory Boardno dataVeri yokVeri yok
Barry Behr
Member of Medical Advisory Boardno dataVeri yokVeri yok
Brad Kolb
Member of Medical Advisory Boardno dataVeri yokVeri yok
Gerard Letterie
Member of Medical Advisory Boardno dataVeri yokVeri yok

7.6yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: PGNY 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 7.6 yıldır).